个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Shao, Z.[1] * ; Huang, T.[2] ; Fan, Z.[3] ; Wang, Y.[4] ; Yan, X.[5] ; Yang, H.[6] ; Wang, S.[7] ; Pang, D.[8] ; Li, H.[9] ; Wang, H.[10] ; Geng, C.[11] ; Huang, L.[12] ; Siddiqui, A.[13] ; Wang, B.[14] ; Xie, B.[15] ; Sun, G.[16] ; Restuccia, E.[17] ;
机构： [1]Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China [2]Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan, Peoples R China [3]Jilin Univ, Dept Breast Surg, Changchun, Peoples R China [4]Shandong Canc Hosp, Breast Canc Ctr, Jinan, Peoples R China [5]Sichuan Univ, West China Hosp, Med Oncol, Chengdu, Peoples R China [6]Zhejiang Canc Hosp, Breast Surg, Hangzhou, Peoples R China [7]Peking Univ Peoples Hosp, Breast Ctr, Beijing, Peoples R China [8]Harbin Med Univ, Dept Breast Surg, Harbin, Peoples R China [9]Beijing Canc Hosp, Breast Canc Ctr, Beijing, Peoples R China [10]Affiliated Hosp Qingdao Univ, Dept Breast Ctr, Qingdao, Peoples R China [11]Fourth Hosp Hebei Med Univ, Breast Ctr, Shijiazhuang, Hebei, Peoples R China [12]Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China [13]Roche Prod Ltd, Prod Dev Clin Oncol, Welwyn Garden City, Herts, England [14]Genentech Inc, Clin Pharmacol, San Francisco, CA 94080 USA [15]Roche China Holding Co Ltd, Biostat, Shanghai, Peoples R China [16]Roche China Holding Co Ltd, PD China, Shanghai, Peoples R China [17]F Hoffmann La Roche Ltd, Prod Dev Oncol, Basel, Switzerland
出处：
ISSN：
基金：
F. Hoffmann-La Roche Ltd.
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Fudan Univ, Shanghai Canc Ctr, Breast Canc, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Shao Z.,Huang T.,Fan Z.,et al.The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study[J].ANNALS OF ONCOLOGY.2022,33:S1431-S1431.
APA：
Shao, Z.,Huang, T.,Fan, Z.,Wang, Y.,Yan, X....&Restuccia, E..(2022).The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study.ANNALS OF ONCOLOGY,33,
MLA：
Shao, Z.,et al."The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in Chinese patients (pts) with HER2-positive early breast cancer (EBC): Primary analysis of the phase III, randomised FDChina study".ANNALS OF ONCOLOGY 33.(2022):S1431-S1431

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号